| Aug 3 |
Blueprint Medicines Second Quarter 2024 Earnings: Beats Expectations
|
| Aug 2 |
Blueprint Medicines (BPMC) Down Despite Q2 Earnings Beat
|
| Aug 2 |
Blueprint Medicines Corporation (BPMC) Q2 2024 Earnings Call Transcript
|
| Aug 1 |
Blueprint Medicines Corporation 2024 Q2 - Results - Earnings Call Presentation
|
| Aug 1 |
Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
|
| Aug 1 |
Blueprint Medicines GAAP EPS of -$0.80 beats by $0.49, revenue of $138.16M beats by $34.22M
|
| Aug 1 |
Blueprint Medicines: Q2 Earnings Snapshot
|
| Aug 1 |
Blueprint Medicines Reports Second Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance
|
| Jul 31 |
Blueprint Medicines Q2 2024 Earnings Preview
|
| Jul 29 |
Earnings Preview: Tango Therapeutics, Inc. (TNGX) Q2 Earnings Expected to Decline
|
